Saturday, November 29, 2014

EPJ Week In Review - Week Ending 11/28/14

Below you'll find everything that has been published on EPJ for the week ended Friday November 28, 2014. The hottest posts for each day are highlighted in red.

Friday 11/28/14
Thursday 11/27/14
Wednesday 11/26/14
Tuesday 11/25/14
Monday 11/24/14
Sunday 11/23/14
Saturday 11/22/14


  1. Hunter Biden & The Carlyle Group: Ukrainian Gasbags

    Boston Globe reported:

    (Vice President Joe) Biden and his wife stayed at the home of Carlyle Group co-founder David Rubenstein and ate a Thanksgiving feast prepared by dinner prepared by Bill Puder, chef at Faregrounds restaurant on the island.

    I'll venture the conversation drifted to Ukrainian gas and how Carlyle's energy infrastructure can help Europe free itself of Russian dependency. USAID came forward to guarantee loans for companies developing energy in Ukraine, Moldova and Georgia. One such firm has a young Biden on its board of directors.

    What was under the PEU serving platter at Mr. Rubenstein's Abrams Point compound? Fortunately, the last four Congresses pardoned carried interest taxation. Now that's service.

  2. VP Biden Eats Carlyle Group Turkey


  3. Failing to Rise to the Challenge What the FDA should learn from Ebola. Dec 1, 2014, Vol. 20, No. 12

    A recent example of the FDA’s indefensible inconsistencies is its October decision to demand more data yet again—without clear, science-based standards—for companies seeking approval for several new drugs that should be available now to patients with the fatal disease of Duchenne muscular dystrophy.

    What makes the muscular dystrophy pronouncements worse is that there are signs that they are driven by the FDA’s worst cultural tendencies: retaliation behind closed doors, “leveling the playing field” for competing companies by slowing down the company in the lead, and improperly relying on outside advisers with a strong financial interest in the outcome of its decisions.

    As the new Congress establishes its oversight priorities, this shameful mess should be high on its list.

    The FDA should learn from its mistakes. It needs to be more proactive with guidance on the standards for approval of drugs for Ebola and other tropical diseases, more transparent about the safety and efficacy of investigational drugs for Ebola, and more understanding about why randomized trials for rare diseases are often not feasible. When it comes to children dying of muscular dystrophy, the FDA needs to show more of the urgency it displayed when approving investigational Ebola drugs for heroic public health workers.

    Michael Astrue is a former commissioner of Social Security and a former HHS general counsel.